Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.8K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.8K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.7K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

88.6K
Overview
88.6K
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

73
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
73

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long term survival in three pancreatic cancer patients following Whipple's procedure and allogeneic hematopoietic cell transplantation.

Frontiers in immunology·2026
Same author

Prospective Double-Blind Randomized Study of Single Dose Bone Marrow-Derived Mesenchymal Stromal Cells versus Placebo for Steroid-Refractory Acute Graft-Versus-Host Disease.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2025
Same author

Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients.

Blood advances·2025
Same author

Artificial intelligence and systems biology analysis in stem cell research and therapeutics development.

Stem cells translational medicine·2025
Same author

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.

Blood advances·2025
Same author

The donor genetic determinant of human thymopoiesis rs2204985 is associated with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients.

Cytotherapy·2025

Related Experiment Video

Updated: Apr 19, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K

GVHD prophylaxis made safe, easy, and inexpensive.

Olle Ringdén1

  • 1KAROLINSKA INSTITUTET.

Blood
|December 16, 2014
PubMed
Summary

Posttransplant cyclophosphamide (Cy) effectively prevents graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplant (HSCT) when used alone. This approach simplifies immunoprophylaxis for HLA-matched transplants.

Area of Science:

  • Hematology
  • Immunology
  • Transplantation

Background:

  • Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplant (HSCT).
  • Current GVHD prophylaxis often involves multiple immunosuppressive agents.
  • Posttransplant cyclophosphamide (Cy) has emerged as a potential alternative for GVHD prevention.

Purpose of the Study:

  • To evaluate the efficacy of posttransplant cyclophosphamide (Cy) as the sole immunoprophylaxis agent against GVHD.
  • To assess outcomes in patients undergoing HLA-matched related or unrelated allogeneic HSCT with Cy-based GVHD prevention.

Main Methods:

  • Retrospective analysis of patients undergoing allogeneic HSCT.
  • Administration of posttransplant cyclophosphamide (Cy) as the only agent for GVHD prophylaxis.

More Related Videos

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

16.3K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.5K

Related Experiment Videos

Last Updated: Apr 19, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K
Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

16.3K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.5K
  • Comparison of outcomes between HLA-matched related and unrelated donor transplants.

    • Main Results:

    • Posttransplant cyclophosphamide (Cy) demonstrated significant efficacy in preventing GVHD.
    • Favorable outcomes were observed in patients receiving Cy as sole immunoprophylaxis.
    • No significant difference in GVHD incidence was noted between related and unrelated donor settings.

    Conclusions:

    • Posttransplant cyclophosphamide (Cy) can be safely and effectively used as a single agent for GVHD prophylaxis in HLA-matched allogeneic HSCT.
    • This strategy simplifies the immunosuppressive regimen, potentially reducing toxicity.
    • Further research should explore long-term outcomes and applicability in different HSCT contexts.